Combinatorial RNA-based gene therapy for the treatment of HIV/AIDS

Expert Opinion on Biological Therapy

Volumn 13, Issue 3, 2013, Pages 437-445

  Chung, Janet ^a   Digiusto, David L ^b   Rossi, John J ^a,b  

^a Beckman Research Institute of City of Hope   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

AIDS; CD34; Gene therapy; Hematopoietic stem and progenitor cells; HIV; Lentiviral vector; Ribozyme; RNA decoy; RNA interference

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; ERDOSTEINE; HYBRID PROTEIN; LENTIVIRUS VECTOR; RECOMBINANT DNA; REV PROTEIN; RIBOZYME; SMALL INTERFERING RNA; SMALL INTERFERING RNA NUCLEOLAR TAR DECOY CCR5 TARGETING RIBOZYME; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIVIRAL ACTIVITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL SUBPOPULATION; DNA MODIFICATION; DNA VECTOR; DRUG APPROVAL; DRUG METABOLISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; GENE EXPRESSION; GENE TRANSFER; HEMATOPOIETIC STEM AND PROGENITOR CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; NONHUMAN; PROGENY; REVIEW; RNA INTERFERENCE; STEM CELL GENE THERAPY; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS ENTRY; VIRUS GENOME; VIRUS RECOMBINANT;

COMBINED MODALITY THERAPY; GENETIC THERAPY; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; RNA; TISSUE THERAPY;

EID: 84873918201     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.761968     Document Type: Review

References (72)

1. Organization, W.H. World health organization: global epidemic data and statistics. 2010. Available from: http://www.who.int/hiv/data/global-data/en/ index.html
2. CDC. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents recommendations of the panel on clinical practices for treatment of HIV*. Morbidity Mortality Weekly Report 2002;51(RR07):1
3. Chun TW, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94(24):13193-7
4. Finzi D, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278(5341):1295-300
5. Wong JK, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278(5341):1291-5
6. Finzi D, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5(5):512-7
7. Calza L. Renal toxicity associated with antiretroviral therapy. HIV Clin Trials 2012;13(4):189-211
8. Jones M, Nunez M. Liver toxicity of antiretroviral drugs. Semin Liver Dis 2012;32(2):167-76
9. Lipshultz SE, et al. HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults. Expert Rev Anti Infect Ther 2012;10(6):661-74
10. Domingo P, et al. Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. AIDS Rev 2012;14(2):112-23
11. Hester EK. HIV medications: an update and review of metabolic complications. Nutr Clin Pract 2012;27(1):51-64
12. Forsyth AD, Valdiserri RO. Reaping the prevention benefits of highly active antiretroviral treatment: policy implications of HIV Prevention Trials Network 052. Curr Opin HIV AIDS 2012;7(2):111-6
13. Camacho R, Teofilo E. Antiretroviral therapy in treatment-naive patients with HIV infection. Curr Opin HIV AIDS 2011;6(Suppl 1):S3-11
14. Scourfield A, Waters L, Nelson M. Drug combinations for HIV: what's new? Expert Rev Anti Infect Ther 2011;9(11):1001-11
15. Williams BG, Lima V, Gouws E. Modelling the impact of antiretroviral therapy on the epidemic of HIV. Curr HIV Res 2011;9(6):367-82
16. Senise JF, Castelo A, Martinez M. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. AIDS Rev 2011;13(4):198-213
17. Vanham G, Van Gulck E. Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1? Retrovirology 2012;9:72
18. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361(23):2209-20
19. Saunders KO, Rudicell RS, Nabel GJ. The design and evaluation of HIV-1 vaccines. AIDS 2012;26(10):1293-302
20. Baltimore D. Gene therapy, Intracellular immunization. Nature 1988;335(6189):395-6
21. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360(7):692-8
22. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia growth and development study, multicenter AIDS Cohort study, multicenter hemophilia cohort study, San Francisco City Cohort, ALIVE study. Science 1996;273(5283):1856-62
23. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86(3):367-77
24. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2(11):1240-3
25. Michael NL, Louie LG, Sheppard HW. CCR5-delta 32 gene deletion in HIV-1 infected patients. Lancet 1997;350(9079):741-2
26. Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011;117(10):2791-9
27. Parker R, Sereti I. The power of 1 in HIV therapeutics. Blood 2011;117(10):2746-7
28. Digiusto DL, Kiem HP. Current translational and clinical practices in hematopoietic cell and gene therapy. Cytotherapy 2012;14(7):775-90
29. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 2011;12(5):2209-20
30. Burnett JC, Zaia JA, Rossi JJ. Creating genetic resistance to HIV. Curr Opin Immunol 2012;24(5):625-32
31. Kiem HP, et al. Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell 2012;10(2):137-47
32. Mitsuyasu RT, et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 2009;15(3):285-92
33. DiGiusto DL, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010;2(36):36ra43
34. van Lunzen J, et al. ransfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther 2007;15(5):1024-33
35. Chung J, Rossi JJ, Jung U. Current progress and challenges in HIV gene therapy. Future Virol 2011;6(11):1319-28
36. Kim SS, et al. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther 2010;18(2):370-6
37. Shimizu S, et al. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood 2010;115(8):1534-44
38. Kiem HP, et al. Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo. Gene Ther 2010;17(1):37-39
39. An DS, et al. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci USA 2007; 104 (32) 13110-5
40. Cagnon L, Rossi JJ. Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts. Antisense Nucleic Acid Drug Dev 2000;10(4):251-61
41. Holt N, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010;28(8):839-47
42. Trobridge GD, et al. Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One 2009;4(11):e7693
43. Nakayama EE, Shioda T. Anti-retroviral activity of TRIM5 alpha. Rev Med Virol 2010;20(2):77-92
44. Smith JL, et al. Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends Pharmacol Sci 2009;30(12):638-46
45. Albin JS, Harris RS, et al. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med 2010;12:e4
46. Wissing S, Galloway NL, Greene WC. HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med 2010;31(5):383-97
47. Evans DT, et al. BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol 2010;18(9):388-96
48. Douglas JL, et al. The great escape: viral strategies to counter BST-2/tetherin. PLoS Pathog 2010;6(5):e1000913
49. Lee NS, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002;20(5):500-5
50. Michienzi A, et al. Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA. Proc Natl Acad Sci USA 2000;97(16):8955-60
51. Unwalla HJ, et al. Use of a U16 snoRNA-containing ribozyme library to identify ribozyme targets in HIV-1. Mol Ther 2008;16(6):1113-9
52. Michienzi A, Li S, Zaia JA, Rossi JJ. A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci USA 2002;99(22):14047-52
53. Bevec D, et al. Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. Proc Natl Acad Sci USA 2002;89(20):9870-4
54. Bonyhadi ML, et al. RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication. J Viro 1997;71(6):4707-16
55. Buonomo SB, et al. The Rev protein is able to transport to the cytoplasm small nucleolar RNAs containing a Rev binding element. RNA 1999;5(8):993-1002
56. Blomer U, Naldini L, Verma IM, et al. Applications of gene therapy to the CNS. Hum Mol Genet 1996;5(Spec No):1397-404
57. Naldini L, Blomer U, Gage FH, et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996;93(21):11382-8
58. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272(5259):263-7
59. Kafri T, Blomer U, Peterson DA, et al. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997;17(3):314-17
60. Yam PY, Li S, Wu J, et al. Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther 2002;5(4):479-84
61. Li MJ, et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther 2003;8(2):196-206
62. Li MJ, et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005;12(5):900-9
63. Emerman M, Malim MH. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 1998;280(5371):1880-4
64. Sirven A, Pflumio F, Zennou V, et al. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 2000;96(13):4103-10
65. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999;73(4):2886-92
66. Baum CM, Weissman IL, Tsukamoto AS, et al. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 1992;89(7):2804-8
67. Craig W, Kay R, Cutler RL, Lansdorp PM. Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med 1993;177(5):1331-42
68. Podsakoff GM, Engel BC, Carbonaro DA, et al. Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol Ther 2005;12(1):77-86
69. Neff T, Beard BC, Kiem HP. Survival of the fittest: in vivo selection and stem cell gene therapy. Blood 2006;107(5):1751-60
70. Persons DA, Allay JA, Bonifacino A, et al. Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors. Blood 2004;103(3):796-803
71. Hanazono Y, Nagashima T, Takatoku M, et al. In vivo selective expansion of gene-modified hematopoietic cells in a nonhuman primate model. Gene Ther 2002;9(16):1055-64
72. Maier P, Spier I, Laufs S, et al. Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O(6)-methylguanine-DNA methyltransferase(P140K). Gene Ther 2010;17(3):389-99